Literature DB >> 24778316

Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer cells.

Valérie Janelle1, Marie-Pierre Langlois, Esther Tarrab, Pascal Lapierre, Laurent Poliquin, Alain Lamarre.   

Abstract

Although the role of the complement system in cancer development has been studied, its involvement in the development of an antitumoral immune response remains poorly understood. Using cobra venom factor (CVF) to inhibit the complement cascade via C3 molecule exhaustion in immunocompetent mice bearing B16gp33 melanoma tumors, we show that transient inhibition of the complement system allowed for the development of a more robust gp33-specific antitumoral CD8(+) T-cell response. This immune response proved to be natural killer (NK) dependent, suggesting an interaction of complement proteins with this cellular subset leading to T lymphocyte activation and enhanced cytotoxic T-cell activity against tumor cells. This study demonstrates for the first time the implication of the complement system in the development of NK-mediated cytotoxic T-cell-dependent antitumoral immune responses. The complement pathway could therefore be a potent therapeutic target to improve NK-dependent antitumoral immune responses in patients with cancer. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24778316     DOI: 10.1158/2326-6066.CIR-13-0173

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  27 in total

1.  Mutation Drivers of Immunological Responses to Cancer.

Authors:  Eduard Porta-Pardo; Adam Godzik
Journal:  Cancer Immunol Res       Date:  2016-07-11       Impact factor: 11.151

2.  Suppression of Ehrlich carcinoma growth by cobra venom factor.

Authors:  T I Terpinskaya; V S Ulashchik; A V Osipov; V I Tsetlin; Yu N Utkin
Journal:  Dokl Biol Sci       Date:  2016-11-08

Review 3.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

Review 4.  Deciphering the Intricate Roles of Radiation Therapy and Complement Activation in Cancer.

Authors:  Jacob Gadwa; Sana D Karam
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-07-03       Impact factor: 7.038

Review 5.  Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.

Authors:  Alexander David Barrow; Marco Colonna
Journal:  Semin Immunol       Date:  2017-09-19       Impact factor: 11.130

6.  The Benefits of Complement Measurements for the Clinical Practice.

Authors:  Anne Grunenwald; Lubka T Roumenina
Journal:  Methods Mol Biol       Date:  2021

7.  Genetic polymorphism in HLA-G 3'UTR 14-bp ins/del and risk of cancer: a meta-analysis of case-control study.

Authors:  Tao Li; Haohai Huang; Dan Liao; Huahuang Ling; Bingguang Su; Maode Cai
Journal:  Mol Genet Genomics       Date:  2015-01-09       Impact factor: 3.291

8.  Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2.

Authors:  Julien Cherfils-Vicini; Charlene Iltis; Ludovic Cervera; Sabrina Pisano; Olivier Croce; Nori Sadouni; Balázs Győrffy; Romy Collet; Valérie M Renault; Martin Rey-Millet; Carlo Leonetti; Pasquale Zizza; Fabrice Allain; Francois Ghiringhelli; Nicolas Soubeiran; Marina Shkreli; Eric Vivier; Annamaria Biroccio; Eric Gilson
Journal:  EMBO J       Date:  2019-04-18       Impact factor: 11.598

9.  Tumor microenvironment-associated gene C3 can predict the prognosis of colorectal adenocarcinoma: a study based on TCGA.

Authors:  Y Liu; X Wang
Journal:  Clin Transl Oncol       Date:  2021-03-25       Impact factor: 3.405

Review 10.  Context-dependent roles of complement in cancer.

Authors:  Lubka T Roumenina; Marie V Daugan; Florent Petitprez; Catherine Sautès-Fridman; Wolf Herman Fridman
Journal:  Nat Rev Cancer       Date:  2019-10-30       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.